Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
featured
A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus.

A multinational, randomized, double-blind, placebo controlled trial to evaluate the effect of Ticagrelor 90mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in

  • 70 views
  • 23 Nov, 2020
  • 1 location
Ticagrelor De-escalation Strategy in East Asian Patients With AMI

Ticagrelor as nonthienopyridine, direct-acting P2Y12 receptor antagonist, had significantly greater platelet inhibition, which could reduce ischemic events at acute phase, however, resulting in

  • 0 views
  • 23 Feb, 2021
  • 1 location
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has

ticagrelor
  • 0 views
  • 11 Feb, 2021
  • 1 location
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation

avoid thromboembolic complications. But the risk of bleeding events with DAPT in this population is not negligible. This study aims to determine the degree of response to Ticagrelor 60 mg every

  • 0 views
  • 25 Jan, 2021
  • 1 location
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

despite contemporary secondary preventative therapy. Compared to aspirin and other antiplatelet therapies like clopidogrel, ticagrelor treatment leads to a more pronounced platelet inhibition, and may

  • 28 views
  • 23 Jan, 2021
  • 2 locations
Phase 2B Study to Evaluate the Efficacy of PB2452 in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

ticagrelor as part of a dual antiplatelet regimen and to evaluate the safety and tolerability of PB2452 in subjects aged 50-80 years old. Approximately 200 subjects between 50-80 years old will be

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients

In this study, the investigates try to confirm our hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in senior no less than

  • 0 views
  • 26 Jan, 2021
  • 1 location
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary

  • 0 views
  • 28 Jan, 2021
  • 1 location
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Patients with symptomatic or asymptomatic carotid stenosis in whom carotid artery stenting is planned are randomised between antiplatelet therapy with ticagrelor plus aspirin or clopidogrel plus

transient ischemic attack
ischemic attack
atherosclerosis
amaurosis fugax
MRI
  • 52 views
  • 03 Feb, 2021
  • 21 locations
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes

dual antiplatelet therapy (DAPT), ticagrelor + aspirin (T+A) or clopidogrel and aspirin (C+A), is the most effective and safest for our patients. While the PLATO trial reported that T+A was superior

antiplatelet therapy
acute coronary syndrome
clopidogrel
plato
aspirin
  • 2 views
  • 26 Jan, 2021
  • 1 location